Two of the three planned phase 3 core efficacy studies in the pivotal clinical plan for ALKS 5461.

Both studies combined are anticipated to randomize approximately 1,000 patients and incorporate sophisticated style features to make sure rigorous patient selection, evaluation and monitoring. Data from both of these core efficacy research are expected in 2016. FORWARD-5, the third primary efficacy trial, is likely to initiate in mid 2014.. Alkermes initiates FORWARD-3 and Forwards-4 efficacy research in pivotal clinical program for ALKS 5461 Alkermes plc today announced the initiation of Forwards-3 and Forwards-4, two of the three planned phase 3 core efficacy studies in the pivotal clinical plan for ALKS 5461, a once-daily, oral investigational medication with a novel system of action for the adjunctive treatment of main depressive disorder .To avail long lasting female laser hair removal solutions, visit.. PRESS RELEASE The Academy of Managed Treatment Pharmacy supports the Department of Health & Human Providers’ proposal announced last week to lessen opioid related misuse, overutilization and abuse by, among other activities, developing new recommendations for prescribing opioids, improving prescription drug monitoring programs and additional adopting electronic prescribing procedures. AMCP Chief Executive Officer Edith A. Rosato, RPh, IOM, issued the following statement: We support HHS’s attempts to expand prescription drug monitoring applications and real-time data posting, as well concerning better integrate details into electronic health information among health professionals.